Universidad Politecnica de Madrid, Spain
THOR coordinator is the Center for Biomedical Technology of the biggest engineering university in Spain, headquarter of international research networks and projects, like the Blue Brain Project.
UPM will provide technological concepts of materials, micromechanics, tissue engineering and biology for the development of THOR technology as well as for building the vascularized DG-hippocampal structure.
-
Prof. Fivos PanetsosBS Appl Mathematics, Spec Artificial Intelligence, PhD Biology (Hons), PhD Medicine (Hons). Over 20 years experience in AI applications, brain-computer interfaces, brain pasticity and neuroregeneration and neurorepair strategies. Founder of several high-tech companies. Professor and Director of the Neurocomputing and Neurorobotics Research Group at Complutense University of Madrid.
UNIVERSITAETSKLINIKUM FREIBURG
One of the top 10 German Universities (top 3 in research funding) and a world leader in neuroscience and neurotechnology, UFR will coordinate WP4 and use its expertise in neuroanatomy, neurophysiology and neuroplasticity for the functional characterization of THOR tissues.
ELVESYS, France
The world most visited microfluidic company, is an international innovative SME, dedicated to microfluidics and organ-on-a-chip devices, which will lead WP2 and design and develop the microfluidic platform, including flow sensors and transportation unit for perfused tissues.
UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI, Italy
With 30 years research expertise in neuroscience, with animal models of neurodegenerative disorders, advanced morphological and functional imaging and in vitro/in vivo molecular analysis, UNA will lead WP3 and test DG-designs' performance by means of 2D and 3D analysis of architectural, functional and biochemical properties of the vascular and neuroglia elements.
BIOACTIVE SURFACES, Spain
A spin-off company of UPM with a revolutionary system for surface biofunctionalization with an extraordinary precision level, will be the responsible for IPR management, protection and translation to the clinic of THOR outcomes in addition to the research work in WP1-WP4.
